NCT00109070已完成3 期
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
This is a multicenter, Phase III, randomized, active-controlled trial to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) added to the standard first-line chemotherapy used to treat metastatic colorectal cancer. This trial will enroll approximately 900 subjects with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Age >=18 years
- •Histologically confirmed colorectal carcinoma with evidence of metastases (i.e., by radiographic imaging or biopsy)
- •Ability to tolerate CT contrast dye
- •Bi-dimensionally measurable disease (minimum of two lesions)
- •ECOG performance status of 0 or 1
- •Use of an effective means of contraception in women of childbearing potential
- •Life expectancy of >3 months
- •Willingness and capability to be accessible for follow-up until death or study termination by Genentech
排除标准
- •Prior chemotherapy other than adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole
- •Administration of adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole completed <=12 months prior to Day 0
- •Administration of fluoropyrimidines as a radiosensitizer during pelvic radiotherapy for rectal cancer completed <=12 months prior to Day 0
- •Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response
- •Radiation therapy within 14 days prior to Day 0
- •Prior biotherapy for colorectal cancer
- •Evidence of clinically detectable ascites on Day 0
- •Other invasive malignancies within 5 years prior to Day 0 (other than basal cell carcinoma of the skin)
- •History or evidence upon physical examination of CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke)
- •Active infection requiring parenteral antibiotics on Day 0
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; fine needle aspirations within 7 days prior to Day 0
- •Current or recent (within the 10 days prior to Day 0) use of full-dose oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanent indwelling IV catheters) or thrombolytic agent (for subjects receiving warfarin, international normalized ratio [INR] of <1.5; appropriate use of heparin should be discussed with the Medical Monitor)
- •Chronic, daily treatment with aspirin (>325 mg/day) or nonsteroidal anti-inflammatory medications (of the kind known to inhibit platelet function at doses used to treat chronic inflammatory diseases)
- •Pregnancy (positive pregnancy test) or lactation
- •Proteinuria at baseline or clinically significant impairment of renal function
- •Serious, nonhealing wound, ulcer, or bone fracture
- •Evidence of bleeding diathesis or coagulopathy
- •Current or recent (within the 28 days prior to Day 0) participation in another experimental drug study
- •Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year prior to Day 0
- •Screening clinical laboratory values: *ANC of <1500/uL; *Platelet count of <75,000/uL; *INR of >=1.5; *Total bilirubin of >1.6 mg/dL; *AST or ALT >=5 times upper limit of normal for subjects with documented liver metastases (>2.5 times the upper limit of normal for subjects without evidence of liver metastases); *Serum creatinine of >2.0 mg/dL; *Hemoglobin of <9 gm/dL (may be transfused to maintain or exceed this level)
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications
研究者
相似试验
已完成
3 期
Aripiprazole IM Depot in the Acute Treatment of Adults With SchizophreniaSchizophreniaNCT03172871Otsuka Beijing Research Institute436
已完成
3 期
A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients with Gastric UlcerGastric UlcerNCT05656092Hanmi Pharmaceutical Company Limited199
已完成
3 期
Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic BronchitisEvaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic BronchitisNCT03489837Hyundai Pharm272
招募中
3 期
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis PatientsRifampin-Resistant Pulmonary TuberculosisTuberculosis, Multidrug-Resistant (MDR-TB)NCT05824871Shanghai Jiatan Pharmatech Co., Ltd450
已完成
3 期
Desidustat in the Treatment of Anemia in CKD on Dialysis PatientsChronic Kidney Disease Stage 5 on DialysisNCT04215120Zydus Lifesciences Limited392